Sirolimus albumin bound(CSPC Zhongqi Pharma)

西罗莫司（白蛋白结合型）（石药集团）

Report date: 2026/03/04 20:01:44

Base Information

Drug NameSirolimus albumin bound(CSPC Zhongqi Pharma)
Drug Alias Name西罗莫司白蛋白结合型
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitors
TargetsSerine/threonine-protein kinase mTOR
Therapy Area/IndicationsGastroenteropancreatic neuroendocrine tumorSolid tumoursHR-positive breast cancer +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroenteropancreatic neuroendocrine tumorSolid tumoursHR-positive breast cancer +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A